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ABSTRACT
Clostridioides difficile disproportionally affects the elderly living in nursing homes (NHs). Our 
objective was to explore the prevalence of C. difficile in NH elders, over time and to determine 
whether the microbiome or other clinical factors are associated with C. difficile colonization.
We collected serial stool samples from NH residents. C. difficile prevalence was determined by 
quantitative polymerase-chain reaction detection of Toxin genes tcdA and tcdB; microbiome 
composition was determined by shotgun metagenomic sequencing. We used mixed-effect random 
forest modeling machine to determine bacterial taxa whose abundance is associated with C. difficile 
prevalence while controlling for clinical covariates including demographics, medications, and past 
medical history.
We enrolled 167 NH elders who contributed 506 stool samples. Of the 123 elders providing 
multiple samples, 30 (24.4%) elders yielded multiple samples in which C. difficile was detected and 
78 (46.7%) had at least one C. difficile positive sample. Elders with C. difficile positive samples were 
characterized by increased abundances of pathogenic or inflammatory-associated bacterial taxa 
and by lower abundances of taxa with anti-inflammatory or symbiotic properties. Proton pump 
inhibitor (PPI) use is associated with lower prevalence of C. difficile (Odds Ratio 0.46; 95%CI, 
0.22–0.99) and the abundance of bacterial species with known beneficial effects was higher in 
PPI users and markedly lower in elders with high C. difficile prevalence.
C. difficile is prevalent among NH elders and a dysbiotic gut microbiome associates with C. difficile 
colonization status. Manipulating the gut microbiome may prove to be a key strategy in the 
reduction of C. difficile in the NH.
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Introduction
Clostridioides difficile infection (CDI), the lead-
ing cause of gastroenterologic hospitalizations 
and associated deaths,1 remains at a historically 
high level with hospital stays from the disease 
tripling over the past decade.2 The elderly are 
disproportionally affected3,4 with the rate of CDI 
being several fold higher in individuals 65 years 
of age and older5 and an increased risk of 2% for 
each additional year after 65 years.6 Not only are 
elders at increased risk of acquiring CDI but 
they also have higher rates of recurrence, com-
plications, and death.7 Elders living in nursing 
homes (NHs) are now the predominant group 
suffering from CDI.3,8 On average, 40% to 50% 
of new CDI cases come from elders living in 
nursing homes.9,10 Most NHs in the US have 
structured infection control and prevention 
programs,11 however environmental measures 
to control CDI, such as enforcing hand hygiene, 
contact precautions, and decontamination proce-
dures are employed only after CDI is identified. 
These measures have not been able to stem CDI 
concerns in NHs.12
One factor that has become of increasing contem-
porary interest and a target of preventive strategies is 
the human gut microbiome. The microbiome is 
a vast ecosystem of microbes that can influence 
human health and disease.13 The intestinal flora 
changes with age, especially as the presence of anae-
robes decreases.14,15 Elders from nursing homes dif-
fer from community-dwelling counterparts as their 
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microbiome composition has a higher proportions 
of the phylum Bacteroidetes and decreased abun-
dances of other bacteria beneficial to human health, 
at the genus levels.16,17 Dysbiosis is a term describing 
a microbial imbalance or maladaptation on or inside 
the body and can be defined as either the loss or gain 
of bacteria which promote health or disease.18,19 The 
microbiome of nursing home elders forms 
a dysbiotic pattern with increasing age, frailty, and 
malnutrition scores.20 These microbial dysbiosis pat-
terns have associations with different disease states, 
however connecting these NH dysbiotic patterns to 
C. difficile colonization and attempting to correct 
them may serve as a means to prevent disease spread. 
Another target for CDI prevention is reducing the 
prevalence of C. difficile in the environment. The 
prevalence of C. difficile in stool is the highest 
among those living in nursing homes with 20% to 
50% of residents affected, compared to 1.6% in the 
general community and 9.5% in the outpatient 
setting.14,21 Higher prevalence of asymptomatic 
colonization with C. difficile is a well-documented 
source of new CDI cases with spread of the bacteria 
to vulnerable individuals, however approaches to 
managing colonization as a means to prevent CDI 
are lacking.22–24
Currently, there is a lack of knowledge concerning 
the risk factors contributing to C. difficile colonization 
in NH elders. A better understanding of how clinical 
factors and microbiome composition contribute to 
C. difficile colonization in NH elder would provide 
a novel tool for preventing CDI. Accordingly, we set 
out to follow longitudinally a cohort of elders from 
multiple NH facilities to investigate: 1) the patterns of 
C. difficile colonization; 2) the associations of 
C. difficile colonization with medication exposures 
and other clinical variables; and 3) the associations 
of C. difficile colonization with characteristics of the 
elder gut microbiome. Our findings contribute to the 
understanding of microbiome composition as 
a potential target to reduce CDI burden in the elderly.
Results
Characteristics of the study subjects
Over a 3-year period, we enrolled and followed 167 
NH elders from 5 different facilities collecting 
monthly samples, totaling 506 clinical samples. 
Forty-four (26.35%) of the residents enrolled pro-
vided only a single stool sample for the following 
reasons: 23 (52.3%) elders were on a floor where 
multiple sample collection did not occur, 12 
(27.3%) residents chose to withdraw from the 
study, 5 (11.4%) died after the first sample collec-
tion, 3 (6.8%) had their nurse stop collection due to 
social issues and, 1 (2.3%) moved out of the facility. 
Of the remaining, we had an average of 3.7 samples 
collected per elder. No residents included in this 
analysis were exposed to antimicrobials nor were 
hospitalized during the study period. The average 
participant age was 85.2 years (SD 9.1) of which 
18.1% were male, 40 (23.9%) were hospitalized in 
the past year, and 31 (18.7%) had an antimicrobial 
exposure in the 6-months preceding enrollment. 
Both frailty and malnutrition were prevalent with 
an average clinical frailty score of 6.5 (s = 1.0) or 
halfway between moderate and severely frail, and 
a malnutrition indicator categorical score of 2.1 
(s = 0.7). Of note, no residents experienced diar-
rheal symptoms nor were diagnosed with CDI dur-
ing the course of this study.
A majority of NH elders have detectable 
C. difficile with one quarter of elders colonized 
over multiple timepoints
Of the 506 samples collected 122 (24.1%) were 
positive for C. difficile. Over the course of the study, 
78 (46.7%) elders had at least one time point in 
which C. difficile was detected in their stool. Across 
all five sites, the prevalence of C. difficile from the 
first elder stool sample taken was 24.0%. For elders 
with serial sampling, 52 (9.7%) elders had C. difficile 
positive samples following a previous C. difficile 
negative sample; 57 (10.6%) elders had C. difficile 
negative samples following a previous C. difficile 
positive sample. On average there was just over 
1 month between sampling timepoints (48.8 days, 
38.9 sd). For elders that went from undetectable to 
detectable (U > D) there were on average 51.1 days 
and 40.0 days from detectable to undetectable 
(D > U) elders. Among elders with multiple positive 
samples, the average time difference between posi-
tive samples was 42.6 days (sd 25.0). There was no 
significant difference between the five sites in 
the percent of serial sampling that changed the 
C. difficile status. Site 4, however, had a higher pre-
valence of C. difficile (p = .048), as determined from 
first samples collected per elder (Figure 1).
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Of the 123 elders with multiple samples, there 
were 41 (33.3%) with a single positive sample and 
30 (24.4%) with multiple samples positive for 
C. difficile. The number and percentage of residents 
colonized by C. difficile did not vary significantly by 
the nursing home facility nor floor/wing in which 
the elder lived. We did not observe any significant 
differences in resident demographics nor clinical 
scores (both frailty and malnutrition) between 
colonized and non-colonized residents (Table 1). 
The only medication significantly associated with 
C. difficile colonization (single and multiple) was 
proton pump inhibitors (Table 1). Remarkably, 
elders taking a PPI daily were 63% less likely to be 
colonized with C. difficile (OR 0.37, 95%CI 
0.17,0.82). No other medication showed any signif-
icant associations and the only medical condition 
associated with colonization was a history of 
a cerebrovascular accident (CVA). Residents colo-
nized with C. difficile had a non-statistically signifi-
cant higher percentage of an antibiotic exposure 
within the preceding 6 months.
Dysbiotic microbiome profile associates with 
clostridioides difficile colonization
Using longitudinal shotgun metagenomic sequen-
cing reads from our NH elders profiled for micro-
bial species abundances with Metaphlan225 in 
combination with demographic, clinical, and med-
ication data we sought to investigate what micro-
biome and clinical features associate with higher 






















Figure 1. Mean percentage of initial samples testing positive for 
C. difficile (prevalence) by nursing home facility site and subse-
quent samples that changed from undetectable to detectable 
(U > D) and detectable to undetectable (D > U). This data 
represents the percentage from the initial and all subsequent 
patient samples where the following sample changed status. 
Error bars depict 95% confidence intervals.
Table 1. Clinical characteristics among residents that were colonized with clostridium difficile at one time point, multiple time points, or 
none.
None (52) One (41) Multiple (30) p-value
Demographics
Age (mean [SD]) (yr) 84.6 (10.2) 86.3 (9.7) 87.3 (6.5) 0.40
Gender Male 11 (21.1) 6 (14.6) 2 (6.7) 0.21
Clinical Frailty Score (mean [SD]) 6.4 (1.0) 6.7 (0.4) 6.3 1.0) 0.50
Malnutrition (mean [SD]) 2.1 (0.7) 2.1 (0.7) 1.9 (0.7) 0.78
CCI Score (mean [SD]) 0.8 (1.7) 0.8 (1.7) 1.1 (1.9) 0.74
Polypharmacy 24 (46.2) 13 (31.7) 14 (46.7) 0.30
Antibiotic Exposure 6 (11.5) 11 (26.8) 7 (23.3) 0.15
Hospital Exposure 16 (30.8) 9 (22.0) 5 (16.7) 0.33
Medications (only those with p < .10)
PPI 22 (42.3) 7 (17.5) 8 (26.7) 0.033
Other Medications in Model
GABA Analogs 6 (11.5) 5 (12.5) 7 (23.3) 0.31
Benzodiazepines 6 (11.5) 4 (10.0) 7 (23.3) 0.23
Valproic Acid 0 (0.0) 2 (5.0) 1 (3.3) 0.29
Thiazide diuretics 0 (0.0) 1 (2.5) 1 (3.3) 0.45
Antiplatelet Medications 4 (7.7) 2 (5.0) 0 (0.0) 0.30
Oral Medications for Diabetes 3 (5.8) 2 (5.0) 0 (0.0) 0.42
Past Medical History
Alzheimer’s Disease 12 (23.1) 14 (34.1) 4 (13.3) 0.13
CVA mild 6 (11.5) 1 (2.5) 6 (20.0) 0.061
CVA severe 0 (0.0) 0 (0.0) 2 (6.7) 0.044
Data presented in number (%) unless otherwise specified. CCI, Charlson comorbidity index. CVA, cerebrovascular accident. PPI, proton pump inhibitor. 
Polypharmacy is 8 or more daily medications. We used chi-square tests to compare categoric variables and the Student’s t test for continuous variables.
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environment. We identified a total of 789 species, 
and after applying a 10% prevalence cutoff we 
ended up with 218 which we used for the remainder 
of the analysis. We started by applying unsuper-
vised learning methods, such as correspondence 
analysis and t-Distributed Stochastic Neighbor 
Embedding (t-SNE), and, as expected, found that 
interindividual variability overwhelmingly 
accounted for the majority of the information in 
the data (Supplemental Figure 1). Therefore, in 
order to identify microbiome features that are asso-
ciated with C. difficile colonization, while also 
accounting for patient-specific effects, we chose to 
apply mixed-effect random-forest regression.26,27 
This modeling approach has significant advantages 
compared to traditional multi-linear regression 
techniques, as it is agnostic to model structure 
(e.g. non-parametric regression), it does not need 
to meet common assumptions underlying classical 
regression techniques and is able to intrinsically 
perform ranked feature selection. We modeled the 
relative abundance of every species as a function of 
patient’s sex, age, PPI (yes/no), antibiotic in the last 
6 months (yes/no), GABA Analogs (yes/no), 
Benzodiazepines (yes/no), Valproic Acid (yes/no), 
Thiazide diuretics (yes/no), Antiplatelet 
Medications (yes/no), Oral Medications for 
Diabetes (yes/no), and C. difficile prevalence 
(Never, One time Point, Multiple Time points, as 
0, 1, 2). Because PPI was found to associate with 
lower C. difficile colonization (Table 1), we 
hypothesized that this could be microbiome- 
mediated and hence included in the modeling 
a C. difficile-PPI interaction term. Finally, the 
patient identifier was used as a random effect. The 
final model that we trained to data was therefore of 
the form Xs;i ¼ f CCð Þ þ 1jID, where X is the rela-
tive abundance of species s in sample i, f is a general 
non-linear function (the random forest) applied to 
the Clinical Covariates (CC) as fixed effects and 
1jID corresponds to the random effect to account 
for multiple samples from the same patient. The 
advantage of this approach is that it allows training 
using multiple samples from the same patients 
without needing to average them out. We used 
permutated importance analysis to determine sig-
nificance of covariates in predicting microbe 
abundances.28
From the modeling, we identified 55 different 
bacterial species whose abundances were signifi-
cantly associated with C. difficile colonization. We 
categorically stratified C. difficile colonization for 
a b
Figure 2. Results from mixed-effect random forest modeling identifies bacteria significantly associated (BH adjusted <0.05) with 
C. difficile colonization in NH elders. (a) We report barplots showing the average ± standard deviation of the abundance of CD- 
colonization significantly associated microbes in patients never, once or with multiple samples colonized by C. difficile. The average 
was calculated from each patient average across multiple microbiome samples. Averaging across patient is only for visualization 
purpose as the mixed-effect random forest modeling explicitly considered each sample from every patient. (b) heatmap displaying the 
log fold change between the average abundance in patients once or multi-colonized over those never colonized by C. difficile. 
Heatmap shows that bacteria with known symbiotic or health-associated properties (including SCFA-producers from the clostridium 
cluster IV an XIVa) are reduced at higher C. difficile colonization. Oppositely, bacteria associated to gastrointestinal dysbiotic conditions 
are enriched in elders with higher C. difficile prevalence. Red color indicates fold change increase in C. difficile colonization status while 
blue is decrease. Species bolded are otUs that overlap with Figure 3.
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each patient by the number of positive samples (i.e. 
Never, Once, and Multiple) (Figure 2a).
There are several patterns that emerge from this 
analysis. First, bacterial taxa that are beneficial to 
human health are enriched in elders without 
C. difficile. For example, multiple butyrate- 
producing organisms in the Eubacterium genus29 
along with taxa such as Odoribacter laneus, Alistipes 
shahii, and Parabacteroides distasonis30–32 have 
higher relative abundance in elders with no 
C. difficile and progressively lower relative abun-
dance in Once and Multiple colonization groups. 
When confirmed that butyrate production capacity 
was reduced at higher prevalence of C. difficile colo-
nization by repeating the same modeling analysis 
but this time predicting the abundance of metabolic 
pathways inferred by running humann233 on the 
metagenomic data. Among the 211 pathways sig-
nificantly associated with C. difficile prevalence 
(p-value BH adjusted <0.05 (Supplementary 
Figure S2), we found that both pyruvate fermenta-
tion to butyrate and the superpathway of clostri-
dium acetobutylicum acidogenic fermentation were 
reduced in elders colonized Once or Multiple times 
with C. difficile compared to None.
Second, both inflammatory-type and pathobiont 
species (bacteria that cause or promote disease only 
when specific genetic or environmental changes 
have occurred)34 were found to be at higher relative 
abundance among elders with C. difficile. 
Pathogens such as multiple Shigella species, 
Escherichia coli, and Bacteroides fragilis,35–37 all 
increased in abundance, progressing from Never 
to Multiple positive samples. Interestingly, this 
also coincided with higher abundance of the super-
pathway of lipopolysaccharide (LPS) biosynthesis 
in Once and Multiple individuals Supplementary 
Figure S2) which was recently shown to be mostly 
contributed by Bacteroidales and Enterobacteriales 
microbes38 and in an increase in the E. coli-derived 
Figure 3. Results from mixed-effect random forest modeling identifies bacteria with significant (BH adjusted < 0.05) C. difficile 
colonization-PPI interaction terms. The displayed subset are those species that are enriched in PPI = yes in people with no C. difficile 
detected and that decreased with C. difficile colonization.
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superpathways of fatty acids and unsaturated fatty 
acids biosynthesis Supplementary Figure S2). 
Inflammation-associated bacteria Bilophila wads-
worthia, Bacteroides dorei, and Firmicutes 
bacterium,39–41 also showed increased abundances 
in elders with multiple C. difficile positive samples. 
Lastly, taxa that are either resistant to or grow with 
exposure to bile exhibited significantly higher 
abundances among elders with multiple C. difficile 
positive samples. These include Alistipes putredinis, 
Anaerofustis stercorihominis, as well as Bacteroides 
and Bifidobacterium species.30,36,42,43 Hierarchical 
clustering of the fold change abundance, between 
the Once and Multiple positive samples groups 
relative to Never positive group, indicates reduc-
tion of symbiotic (mutually beneficial host–micro-
biome relationship), or health-associated taxa and 
an increase in inflammation-associated taxa, with 
known ability to grow in presence of primary bile 
acids, with Multiple C. difficile colonization 
(Figure 2b).
Sixty-six individuals were characterized by hav-
ing samples both negative and positive for 
C. difficile presence. We therefore asked if the 
microbiota profile change in patients where there 
is a change in C. difficile status both in terms of 
species abundances and overall diversity. We com-
pared Shannon Diversity for samples negative and 
positive with C. difficile using mixed-effect model-
ing and using patient ID as random effect. We 
found no difference in diversity between samples 
positive and negative for C. difficile presence 
(Supplemental Figure 3A). We applied Mixed- 
Effect Random Forest Classification to predict 
C. difficile sample positivity as a function of micro-
bial abundances. The model identified 11 species 
significantly associated with C. difficile sample posi-
tivity, and notably identifies an increase in 
Akkermansia muciniphila and in B. vulgatus in 
C. difficile positive samples (Supplemental Figure 
3B). Interestingly, higher A. muciniphila abun-
dance has also been found in CDI elders compared 
to control groups.44
As we determined that PPI is negatively asso-
ciated with C. difficile prevalence in our bivariate 
analysis (Table 1), we hypothesized that this protec-
tion could be gut microbiota dependent. We there-
fore investigated the microbiota species that were 
characterized by having a significant (p-value BH 
adjusted <0.05) C. difficile-PPI interaction coeffi-
cient from the mixed-effect random forest model-
ing. From these species, we found that a subset 
displaying a greater abundance in PPI-treated elders 
without C. difficile compared to PPI-untreated and 
whose abundance was decreasing with increasing 
C. difficile prevalence. According to these criteria, 
we identified a set of nine species (Figure 3).
Discussion
Nursing home elders demonstrated high C. difficile 
prevalence in our study with over half having at 
least one C. difficile positive sample and 1 in 4 
elders having multiple positive samples. This colo-
nization pattern suggests, and we further hypothe-
size, that a subset of elders in the NH may serve as 
a source of transmission to other individuals. In an 
attempt to better understand these individuals, we 
looked for clinical and microbiome associations. 
Among the clinical, we found daily proton pump 
inhibitor exposure was associated with a 63% 
reduced risk of C. difficile colonization (i.e. more 
non-colonized residents were daily PPI users). 
Reduced abundances of symbiotic or butyrate- 
producing organisms and higher abundances of 
pathogenic, inflammatory, or bile acid growing 
bacterial species were associated with C. difficile 
colonization.
Clostridium difficile colonization is common among 
NH elders
The prevalence of C. difficile colonization observed 
in our study is consistent with prior reports that 
have demonstrated a range of colonization in the 
NH environment with prevalence rates as low as 
20% to over 50%.14,21 We have expanded upon 
prior cross-sectional reports by following elders 
longitudinally. We demonstrate not only a high 
prevalence but also patterns of colonization where 
a subset of elders has multiple C. difficile samples 
over time. Elders with multiple positive samples 
may represent a group of long-term colonized 
elders who are more likely to serve as reservoirs of 
C. difficile relative to those with only one positive 
sample, or transiently colonized elders.
There are few studies of C. difficile colonization 
in the elderly, fewer involving elders living in 
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nursing homes. The systematic review noted above 
did not reveal any association with PPI and 
C. difficile in the elderly.45 Among older hospita-
lized adults, treatment upon admission with PPIs 
has not been shown to be associated with C. difficile 
colonization.46 The use of PPI was also shown not 
to be associated with C. difficile colonization in 
previous studies with a lower number of subjects, 
68 long-term care elders, although a non- 
statistically significant higher percentage of colo-
nized residents were on a PPI.21 Our findings sug-
gest that changes in the intestinal microbiome with 
acid-reducing medication use may be associated 
with a less favorable environment for C. difficile 
colonization.
A dysbiotic gut microbiome composition 
associates with clostridium difficile colonization
Elders in our study with Once and Multiple types of 
C. difficile colonization demonstrated a pattern of 
decreased abundances of symbiotic and/or butyrate- 
producing organisms and consequent reduction in 
pathways leading to butyrate production. These elders 
were found to display increased abundances in patho-
genic, inflammatory, or bile acid growing species, 
along with increased capacity for the production of 
known inflammatory molecules such as LPS.
Butyrate is a short-chain fatty acid that is known 
to contribute to the maintenance of the gut barrier 
functions and has both immunomodulatory and 
anti-inflammatory properties.29 Thus, higher abun-
dances of organisms that produce butyrate are con-
sidered to be beneficial. Among patients with CDI, 
butyrate-producing species have been shown to be 
depleted,47 and butyrate protects against CDI, in 
mouse models by reducing intestinal inflammation 
and increasing epithelial tight junctions.48 Lack of 
butyrate-producing species has been linked to many 
other intestinal disorders such as Crohn’s Disease 
and colorectal cancer.29,49 A lack of butyrate- 
producing organisms in NH elders may contribute 
to a favorable environment for C. difficile 
colonization.
Multiple pathogenic bacterial species exhibit 
increased relative abundance in C. difficile colo-
nized elders. These include B. fragilis, the most 
commonly isolated anaerobic pathogen,36 
Eggerthella lenta, a significant human pathogen 
that is often associated with serious gastric 
pathology,50 E. coli, and multiple Shigella species, 
which has been reported to be present during CDI 
in elderly NH patients.51,52 Inflammation- 
associated species were also present in higher abun-
dances especially among elders with multiple 
C. difficile positive samples. Species such as 
Proteobacteria bacterium, a commonly found spe-
cies in inflammatory disorders,53 Anaerostipes cac-
cae which is positively associated with CDI in 
Irritable Bowel Disease,54 Bacteroides vulgatus, 
a species that has recently been identified as influ-
encing neuroinflammatory signaling,55 and 
Ruminococcus gnavus, which has been associated 
with a dysbiotic microbiota.56 Taken together, 
higher abundances of pathogenic and inflamma-
tory bacteria associate with C. difficile colonization.
Bile acids, detergent-like biological substances 
synthesized in the liver from cholesterol, play an 
important role in the physiology of intestinal bac-
teria and influence their functionality.43 C. difficile 
is dependent upon accessing and modifying endo-
genous bile salts.57 We observed increased abun-
dances of species that grow when exposed to 
increasing concentrations of bile acids among 
elders with multiple C. difficile positive samples. 
Several members of the Bacteroides genus had 
higher abundances among C. difficile colonized 
elders. In general, Bacteroides is a bile resistant 
genus while Bacteroides fragilis, specifically, is 
known to play a key role in the enterohepatic cir-
culation of bile acids.36 We also found 
Bifidobacterium breve following the same trend as 
another species that survives in bile.43 Interestingly, 
Bifidobacterium longum, which has one of the low-
est survival rates in bile among the Bifidobacterium 
genus,58 was found at lower abundances among 
C. difficile colonized elders. Other species following 
this trend of growth in bile and higher abundances 
in C. difficile colonized elders include Alistipes 
putredinis,59 Anaerofustis stercorihominis,42 
Bilophila wadsworthia,60 and the pathogens 
Shigella and Escherichia coli.61 It is thought that 
decreases in secondary bile acids may provide 
a favorable environment in which C. difficile can 
grow and colonize.62
Proton pump use associates with protection 
against C. difficile colonization via commensal 
gut bacteria
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Proton pump inhibitors have been known for 
quite some time to be associated with an increased 
risk of CDI.6 A recent large systematic review and 
meta-analysis including 56 studies involving 366,683 
patients demonstrated a two times increased risk of 
CDI with PPI use.45 However, whether this is causa-
tion or association is still up for debate given that the 
exact mechanism of action is unknown.63,64 Proton 
pump inhibitors are one type of medication that 
changes both overall diversity and the relative abun-
dances of specific bacterial taxa.65 Besides diversity, 
differences among bacterial species composition in 
the intestines between PPI users and non-users are 
consistently associated with changes toward 
a dysbiotic gut microbiome and are in line with 
known changes in the microbiome that predispose 
individuals to CDI.66,67 With regards to colonization, 
PPIs have been shown not to promote C. difficile 
colonization in murine models,68 and a more recent 
prospective observational study among older hospi-
talized adults demonstrated no relationship between 
PPI use and C. difficile colonization.46 In other nur-
sing home investigations, the use of PPI had a non- 
significant inverse relationship with C. difficile colo-
nization however among a much smaller cohort.21
Here we are reporting on the association of lower 
risk for C. difficile colonization among nursing home 
elders taking a PPI daily and propose that a possible 
mechanism lies in the differences in microbiome 
composition between users and non-users of PPIs. 
Among non-colonized elders taking a PPI, we 
noticed enrichment in gut bacteria such as 
Eubacterium species and Faecalibacterium prausnit-
zii. The Eubacterium spp. are an important butyrate- 
producing bacterial species which contributes to the 
maintenance of the gut barrier functions, and has 
both immunomodulatory and anti-inflammatory 
properties.29 Faecalibacterium prausnitzii, one of 
the most abundant and important butyrate com-
mensal bacteria of the human gut microbiota,69,70 
also show enrichment in non-colonized PPI users. 
The subset of species displaying a greater abundance 
in PPI-treated elders without C. difficile compared to 
PPI-untreated and whose abundance was decreasing 
with increasing C. difficile prevalence included spe-
cies five (C. symbiosum, D. longicatena, E. eligens, 
E. rectale and F. prausnitzii) belong to the 
Clostridiales order. These species have also been 
associated with protection against inflammatory 
and infectious conditions in both mice and humans, 
including C. difficile infection.71–73 Vincent et al. 
(2013) found that Eubacteria and Faecalibacterium 
are depleted in CDI patients.73 It additionally 
reported a decrease in the family Bacteroidaceae, 
which is consistent with our analysis finding 
B. uniformis enriched in PPI with no CD and 
reduced with higher prevalence of C. difficile, an 
association noted by others.74–76 Our findings sug-
gest that changes in the intestinal microbiome 
among elders exposed to a PPI may be associated 
with a less favorable environment for C. difficile 
colonization.
Strengths and limitations
This study had several notable strengths and limita-
tions. One limitation of this study is that it did not 
have four stool samples from each resident. This may 
have led to misclassification of the secondary out-
come of multi-colonization in these residents. This is 
the largest longitudinal cohort of nursing home 
elders reporting microbiome composition. It is also 
the largest study to survey NH residents for 
C. difficile colonization. That being said this study 
is still limited in the number of residents enrolled. 
A more robust cohort would help us to take a much 
deeper look at the multiple levels of data and to 
better explore other classes of medications used less 
frequently by NH elders. There are potential con-
founding variables, specifically classes of medica-
tions the residents were taking (such as 
corticosteroids and immunosuppressants) that were 
not evaluated in this cohort due to the small number 
of residents on these drugs. Following up this inves-
tigation with a cohort including larger numbers of 
residents from more facilities would strengthen the 
findings and further explore the dysbiosis associa-
tions with medication exposure in the elderly and 
further address how these dysbiotic patterns are 
associated with C. difficile colonization.
Conclusions
In conclusion, C. difficile colonization is common 
among NH elders with a large portion of these 
colonized residents harboring this pathogen over 
the course of months. C. difficile colonization state 
was associated with an inverse relationship to PPI 
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medication use and key healthy bacterial species are 
present in elders using a PPI who do not demon-
strate colonization. Finally, we found that the abun-
dances of several key intestinal bacterial species 
were associated with C. difficile colonization and 
thus describe a dysbiotic environment in which 
C. difficile can take residence and thrive. This 
microbiome is described as having lower abun-
dances of symbiotic or butyrate-producing organ-
isms with increased abundances of organisms that 
utilize bile acids or are considered pro- 
inflammatory or pathogenic bacterial species. 
Further work is needed to see if promoting an 
elder gut microbiome composition to one that 
resists colonization could affect the high rates of 
C. difficile colonization seen within the nursing 
home environment, thus providing a novel 
approach at preventing this devastating disease.
Patients and methods
Study setting and population
This prospective cohort study was approved by the 
institutional review board at the University of 
Massachusetts Medical School. This cohort is of NH 
residents ≥65 years of age who lived in one of five NH 
facilities in central Massachusetts. We approached 
residents who had been living in the facility for 
≥1 month and did not have any diarrheal illness or 
antimicrobial exposure within the preceding 4 weeks. 
Our trained staff used a standardized Capacity for 
Informed Consent Instrument77 that combines capa-
city assessment questions with observation. If the 
resident was deemed unable to provide consent, we 
contacted the healthcare proxy to obtain informed 
consent. Residents were enrolled for a minimum of 
4 months. All residents across the four facilities fol-
lowed similar low-fiber diets and at each nursing 
facility, all the elders were fed the same meals that is 
typical for a nursing home diet. No patients suffered 
from dysphagia or had a feeding tube.
Data collection
We conducted baseline and end of study medical 
record abstraction for factors associated with key 
study outcomes. These factors included: age, nutri-
tional status, comorbidities, all medications, and 
frailty.16 Prior history of hospitalizations within the 
past year and antibiotic exposures in the past six 
months were collected from the medical record. 
Both daily and as needed medications were obtained 
from the facility’s medical record. Polypharmacy was 
defined using the most commonly reported defini-
tion of five or more daily medications.78 
Polypharmacy has been shown to represent 
a determinant of gut microbiota composition inde-
pendent of specific drug classes that have detrimental 
clinical consequences.79 We also obtained age, sex, 
race, and length of NH stay from the medical record. 
Clinical scoring systems were made from elders dur-
ing baseline interviews and corroborated from 
family or facility staff. We used the Charlson 
Comorbidity Index (CCI) to categorize patients’ 
medical comorbidities.80,81 The CCI is a method of 
predicting mortality by classifying or weighting 
comorbid medical conditions and has been widely 
used to measure the burden of medical diseases.82 
Frailty was categorized according to the validated 
and widely utilized Canadian Study of Health and 
Aging’s (CSHA) 7-point Clinical Frailty Scale 
(CFS).83 This has been previously validated in 
demonstrating signatures of frailty in the gut 
microbiota.20,84,85 This frailly scale goes from very 
fit (1) to very severely frail (8). We did not enroll 
terminally ill patients into this study. We assessed 
nutritional status using the Mini Nutritional 
Assessment (MNA) tool.86–88 The MNA is a rapid 
assessment of nutritional status used routinely in 
elderly NH residents.88 Residents were categorized 
as normal (1), at risk (2), or malnourished (3) based 
on the MNA survey administered to the residents by 
trained research staff or the nurse caring for the 
resident if mentally impaired. All residents enrolled 
were monitored during their involvement in the 
study for any changes to their care or for new med-
ication or hospitalization exposures.
Sample collection, sequence processing, and 
analysis
DNA was extracted from samples using the 
PowerMagTM Soil DNA Isolation Kit on an 
epMotion 5075 TMX liquid handling workstation 
according to manufacture protocols (MO BIO 
Laboratories, #27,100-4-EP). Sequencing libraries 
were constructed using the Nextera XT DNA 
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Library Prep Kit (Illumina, Inc., #FC-131-1096) and 
sequenced on a NextSeq 500 Sequencing System as 
2 × 150 base pair-end reads. Shotgun metagenomic 
reads were first trimmed and quality filtered to 
remove sequencing adapters and host contamination 
using Trimmomatic89 and Bowtie2,90 respectively, as 
part of the KneadData pipeline v0.6.1 (https://bit 
bucket.org/biobakery/kneaddata) using human gen-
ome hg19 (GRCh37, GCA_000001405.1). Reads 
were then profiled for microbial taxonomic abun-
dances using Metaphlan291 and for metabolic path-
way abundance using humann233 (as in our previous 
work).20,27 Statistics for the sequencing is provided 
in Table 2:
Detection C. difficile colonization
All samples were tested for C. difficile toxin genes to 
determine C. difficile colonization. This was done 
using real-time polymerase-chain reaction with 
AdvanSure RT-PCR kit (LG Life Science) for the 
simultaneous detection of tcdA and tcdB genes. 
The primer pairs used were
NK9-NK11 for the repetitive domain of the tcdA 
gene and NK104-NK105 for the tcdB gene. This 
method is based on TaqMan technology and has 
been shown to have very good test characteristics 
with 100% sensitivity and 98.3% specificity.92 We 
used the SLAN RTPCR detection system (LG Life 
Science) according to the manufacturer’s 
instructions.92 Each sample needed to be positive 
for both tcdA and tcdB genes to then be categorized 
as positive for C. difficile. Estimation of C. difficile 
colonization using qPCR instead than directly from 
shotgun metagenomics has been used several times 
previously by us and others93,94 and it allows to 
determine with better resolution the presence of 
this bacterium which is usually found at very low 
abundance in the GI tract (<1%) and could be 
undetected from metagenomic sequencing.
Definition of outcome of C. difficile colonization
We defined “C. difficile colonization” as the detection 
of C. difficile toxin genes A or B using real-time 
polymerase-chain reaction in the absence of any diar-
rheal symptoms 4 weeks pre- and post- sample col-
lection. We further divided C. difficile colonization 
into two categories. The first was elders with only one 
sample testing positive (one-time) while the second 
was if the elder had multiple samples positive (multi-
ple). No elders in this study had diarrhea at any point.
Statistical and computational analysis
Multivariable Logistic Regression Modeling. We 
first used multivariable logistic regression analysis 
to test whether clinical variables alone were asso-
ciated with C. difficile colonization. To select the set 
of covariates for the multivariable model, we 
selected any covariates with a p < .20 from an 
unadjusted bivariate analysis. We ran two models, 
first with the outcome of any colonization time 
point and then again with the outcome of multiple 
colonization time points. We included all acid- 
reducing medications rather than proton pump 
inhibitors alone in the model given that both were 
significantly associated with the outcome.
Descriptive Microbiome Analysis. To determine 
similarity in microbiome samples among the NH 
elders and to associate microbiome features to 
C. difficile colonization level, we started by per-
forming traditional unsupervised correspondence 
analysis, including Principal Component Analysis 
and t-Distributed Stochastic Neighbor Embedding. 
We used functions within the R packages phyloseq, 
vegan, and Rtsne to perform the descriptive micro-
biome analysis (see available code at https://gitlab. 
com/vanni-bucci/2020_cdad_nh_paper).
Machine Learning Analysis. As most of the sig-
nal from the unsupervised analysis was accounted 
by inter-individual variability, we then decided to 
Table 2. Sequencing statistics.
Tot met Tot con R1 met pair R1 met unpair R2 met pair R2 met unpair R1 con pair R1 con unpair R2 con pair R2 con unpair
Min 11,001 22 5221 173 5221 51 2 0 2 4
1st 1,507,492 1405 676,456 33,390 676,456 11,720 424.5 62 424.5 202
Med 3,631,704 3999 1,599,716 145,184 1,599,716 60,103 1515 247 1515 697
Mean 4,882,975 38,199 2,226,512 262,996 2,226,512 166,955 16,293.3 2835 16,293.3 2777
3rd 7,195,878 20,134 3,130,797 392,860 3,130,797 281,778 7913.5 1152 7913.5 1630
Max 31,484,048 2,552,975 14,855,260 1,629,179 14,855,260 1,083,991 1,219,545 159,005 1,219,545 204,963
Met = metagenomics, con = host contamination, pair = paired reads, unpair = unpaired reads
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run supervised machine learning models that 
account for the repeated sampling nature of our 
study design. We therefore run mixed-effect ran-
dom forest modeling to predict the abundance of 
every detected microbiota species as a function of 
clinical covariates and level of C. difficile coloniza-
tion in each individual (see results). As reported in 
the results we used the Mixed-Effect-Random- 
Forest (MERF) routine from R package 
LongituRF95 to fit the model Xs;i ¼ f CCð Þ þ 1jID, 
where (1) X is the relative abundance of species s in 
sample i, (2) f is a general non-linear function (the 
random forest) applied to the Clinical Covariates 
(CC) as fixed effects (which includes C. difficile 
prevalence as ordinal variable 0,1,2) and (3) 1jID 
corresponds to the random effect to account for 
multiple samples from the same patient. We used 
permutated importance analysis to assess the sig-
nificance of the clinical predictors in associating 
with each microbiota species abundance.
To perform the within-patient analysis (e.g., differ-
entiating positive and negative samples for elders that 
switch from negative to positive and vice-versa) we 
first calculated Shannon diversity and performed lin-
ear-mixed effect modeling as 
Diversity ¼ SamplePositivityþ 1jID. To classify sam-
ples as C. difficile positive vs negative, we applied 
Mixed-Effect Random Forest Classification. 
Permutated Importance Analysis was used to deter-
mine species significantly associated with sample 
positivity.
Data availability
Sequences have been deposited in the NCBI SRA under acces-
sion PRJNA529586. Processed data, metadata and code to 
reproduce analysis in the paper is available at https://gitlab. 
com/vanni-bucci/2020_cdad_nh_paper.
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